The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to ³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s report on Cell & gene therapy in pharma: recombinant adeno-associated virus (AAV) gene therapy

Smarter leaders trust GlobalData

Data Insights

Data Insights

The gold standard of business intelligence.

Find out more

According to ³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Recombinant AAV gene therapy is a key innovation area in cell & gene therapy

Recombinant AAV gene therapy is a technique that uses recombinant adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target tissues. AAVs have gained attention due to their ability to provide long-term expression of therapeutic genes without inducing an immune response. Recombinant AAVs are engineered to carry specific therapeutic genes and are used to treat a range of genetic and acquired diseases.

³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 230+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant AAV gene therapy.

Key players in recombinant AAV gene therapy – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to recombinant AAV gene therapy

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Takeda Pharmaceutical 164 Unlock Company Profile
Encoded Therapeutics 115 Unlock Company Profile
Genethon 107 Unlock Company Profile
BioMarin Pharmaceutical 90 Unlock Company Profile
Sanofi 77 Unlock Company Profile
Esteve Pharmaceuticals 68 Unlock Company Profile
Centre National de la Recherche Scientifique 67 Unlock Company Profile
Bayer 61 Unlock Company Profile
Children's Hospital of Philadelphia 57 Unlock Company Profile
Nationwide Children's Hospital 51 Unlock Company Profile
Applied Genetic Technologies 49 Unlock Company Profile
RegenxBio 49 Unlock Company Profile
Astellas Pharma 46 Unlock Company Profile
Sangamo Therapeutics 45 Unlock Company Profile
St. Jude Children’s Research Hospital 44 Unlock Company Profile
Homology Medicines 38 Unlock Company Profile
Biogen 36 Unlock Company Profile
Decibel Therapeutics 34 Unlock Company Profile
Eli Lilly 33 Unlock Company Profile
Adverum Biotechnologies 33 Unlock Company Profile
Syncona 32 Unlock Company Profile
Pfizer 31 Unlock Company Profile
Massachusetts Eye and Ear Infirmary 30 Unlock Company Profile
Benitec Biopharma 30 Unlock Company Profile
Eyeserv 30 Unlock Company Profile
Regeneron Pharmaceuticals 29 Unlock Company Profile
Voyager Therapeutics 28 Unlock Company Profile
UniQure 28 Unlock Company Profile
Fondazione Telethon 28 Unlock Company Profile
Tenaya Therapeutics 27 Unlock Company Profile
Verneuil Participations 22 Unlock Company Profile
Precision Biosciences 22 Unlock Company Profile
Rocket Pharmaceuticals 20 Unlock Company Profile
Life Sciences Research Partners VZW 20 Unlock Company Profile
Generation Bio 20 Unlock Company Profile
4D Molecular Therapeutics 19 Unlock Company Profile
Genepod Therapeutics 19 Unlock Company Profile
AVROBIO 16 Unlock Company Profile
Daiichi Sankyo 15 Unlock Company Profile
SparingVision 15 Unlock Company Profile
MeiraGTx 14 Unlock Company Profile
Children's Medical Center 14 Unlock Company Profile
Ecole Polytechnique Federale de Lausanne 14 Unlock Company Profile
Ultragenyx Pharmaceutical 14 Unlock Company Profile
ToolGen 13 Unlock Company Profile
NeuExcell Therapeutics 13 Unlock Company Profile
Vivet Therapeutics 12 Unlock Company Profile
Sarepta Therapeutics 12 Unlock Company Profile
American Gene Technologies International 12 Unlock Company Profile
UCB 12 Unlock Company Profile

Source: GlobalData Patent Analytics

(Takeda) is one of the leading patent filers in recombinant AAV gene therapy. Takeda is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of medications. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder. Its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. Encoded Therapeutics and Genethon are some of the other key patent filers in recombinant AAV gene therapy.

In terms of application diversity, F. Hoffmann-La Roche leads the pack, while UniQure and Regeneron Pharmaceuticals stood in the second and third positions, respectively.

By means of geographic reach, held the top position, followed by Genepod Therapeutics and .

To further understand the key themes and technologies disrupting the pharmaceutical industry, access ³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s latest thematic research report on .

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, ³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.